Drew Burch Drew Burch

Drew Burch, President of Nucleic Acid Products at TriLink Biotechnologies, has over 30 years of strategic, operational, commercial and financial experience in the life sciences industry. Prior to joining Maravai, he was President of Softgels at Thermo Fisher Scientific, where he led the division’s CDMO services in the U.S. and Europe.

What’s in store for mRNA therapeutics in 2024?

We’re about to see a seismic shift in mRNA therapeutics as the field erupts ...

Drew Burch
Drew Burch
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call